Resignation of the Member of the Management Board - Chief Financial Officer

Current Report No. 5/2024

Date of preparation: February 6th, 2024

Subject: Resignation of the Member of the Management Board - Chief Financial Officer

Legal basis: Article 56 (1) (2) of the Act on Public Offering - current and periodic information

The Management Board of Captor Therapeutics S.A., based in Wrocław (the "Company"), announces that on 6 February 2024, Mr Radosław Krawczyk resigned from his position as Member of the Company's Management Board - Chief Financial Officer for personal reasons, effective as of today.

At the same time, the Company's Management Board announces that it has decided that the tasks and responsibilities remaining with the Member of the Management Board - Chief Financial Officer will at this stage be divided between the other Members of the Management Board, i.e. Thomas Shepherd - President of the Management Board and Michał Walczak - Member of the Management Board, Chief Scientific Officer, as well as Head of Operations - Anna Pawluk, who has become the Company's proxy. Day-to-day financial matters will be managed by the Group Financial Controller - Martyna Kościelna. Both Anna Pawluk and Martyna Kościelna have been working at the Company for many years. Additionally, Radosław Krawczyk will provide consulting services to the Company for certain period after resignation in order to ensure smooth transition of duties.

The Supervisory Board, Management Board and employees of Captor Therapeutics S.A. would like to thank Mr Radosław Krawczyk for his commitment, work and contribution to the development of the Company, wishing him further success in his professional achievements.